so in conclusion adoption of the m r c follow up follow up policy would have resulted in  targeting of cystoscopic follow up to higher risk group patients, a two percent increase in the cystoscopic resources required and delayed diagnosis of tumour progression in one patient, and as i've said i i think that g three p t one tumours should be excluded from  er  this type of protocol.